IW 323

November 19, 2025 Viktor Zarev 0 min read
  1. CMS issues guidance on new tax limits to close Medicaid loophole.
  2. NIH cuts impact 74k clinical trial patients.
  3. New Oracle co-CEO to oversee healthcare division.
  4. FDA confronts risks of therapy chatbots, weighs regulation.
  5. UnitedHealth’s new CFO details plan to restore ‘swagger’.
  6. AdventHealth taps 10 division executives.
  7. Police officer shot and killed in North Carolina hospital.
  8. Kaiser Permanente consolidates 12 EHRs to 2.
  9. AI increasingly responsible for job cuts.
  10. Sutter’s $2.8B Silicon Valley expansion includes a new medical center.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiac Imaging March 12, 2026

IVI or Angiography for Complex PCI Guidance? March 12, 2026

New follow-up data from the RENOVATE-COMPLEX-PCI trial suggests that intravascular imaging continues to provide better clinical outcomes for patients with complex coronary lesions five years after their PCI procedure. The RENOVATE-COMPLEX-PCI trial originally randomized 1.6k patients with complex coronary lesions to receive either IVI or angiography guided PCI and found that IVI led to a […]

Heart Failure March 9, 2026

Barostim Boosts QoL and LVEF, but Mortality Benefit Still Unknown March 9, 2026

Strong results from two separate studies on CVRx’s Barostim baroreflex activation therapy suggest the technology might offer symptomatic relief even though its mortality benefit is still up in the air. The first of two Barostim studies discussed at THT 2026, the REBALANCE registry enrolled 435 patients with a low average baseline LVEF, mostly NYHA class […]

Cardiology Testing March 5, 2026

What NT-proBNP Can Tell Us About TEER Outcomes March 5, 2026

New research presented at THT 2026 suggests that the NT-proBNP biomarker could give us a glimpse into which patients with severe tricuspid regurgitation (TR) will benefit the most from transcatheter edge-to-edge repair (TEER). Using data from the EuroTR registry, researchers evaluated 2.2k patients undergoing TEER, and organized them into three NT-proBNP categories (≤1,674, 1,675-3,743, >3,743 […]